MC2 Therapeutics appoints Trine Ahlgreen as new CEO

27 May 2025

Danish privately-held drugmaker MC2 Therapeutics today announced the appointment of Trine Ahlgreen as chief executive (CEO).

MC2 noted that this marks a new chapter in the company’s journey to unlock the full global potential of its commercial asset, Wynzora Cream (a fixed dose combination of calcipotriene and betamethasone dipropionate, and to maximize the commercial potential of its formulation and drug delivery system, PAD Technology.

With an extensive background spanning commercial leadership of global, regional and local pharmaceutical product launches, leadership of several successful cross-functional teams and business development across Europe, the USA and Japan, Ms Ahlgreen brings a breadth of experience to MC2 Therapeutics.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK